tiprankstipranks
SciBase Holding AB (SE:SCIB)
:SCIB
Want to see SE:SCIB full AI Analyst Report?

SciBase Holding AB (SCIB) AI Stock Analysis

0 Followers

Top Page

SE:SCIB

SciBase Holding AB

(SCIB)

Select Model
Select Model
Select Model
Neutral 47 (OpenAI - 5.2)
Rating:47Neutral
Price Target:
kr0.46
▲(40.30% Upside)
Action:Reiterated
Date:05/14/26
The score is held down primarily by very weak financial performance—large operating losses and significant ongoing cash burn—despite decent revenue growth and manageable leverage. Technicals are supportive (uptrend with positive MACD), but overbought signals (RSI/Stoch) add near-term risk. Valuation is constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Recurring consumable revenue
SciBase’s business model includes recurring, usage-linked sales of consumables and single-use components tied to installed devices. This creates repeatable revenue streams and lifetime customer value, improving long-term revenue visibility and supporting margin scalability as installed base grows.
Negative Factors
Very large operating losses
Operating losses vastly exceed revenues on a TTM basis, indicating the cost base is far ahead of current commercial traction. Such structural unprofitability undermines internal funding capacity and prolongs the timeline to sustainable earnings without material cost reduction or outsized revenue acceleration.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumable revenue
SciBase’s business model includes recurring, usage-linked sales of consumables and single-use components tied to installed devices. This creates repeatable revenue streams and lifetime customer value, improving long-term revenue visibility and supporting margin scalability as installed base grows.
Read all positive factors

SciBase Holding AB (SCIB) vs. iShares MSCI Sweden ETF (EWD)

SciBase Holding AB Business Overview & Revenue Model

Company Description
SciBase Holding AB (SCIB) is a Swedish medical technology company that specializes in developing innovative diagnostic solutions for skin cancer detection and monitoring. The company operates primarily in the healthcare sector, focusing on non-inv...
How the Company Makes Money
SciBase primarily makes money by selling and supporting its diagnostic platform for skin assessment used in clinical settings. Revenue is generated from (1) system-related sales (the placement/sale of Nevisense devices to clinics and hospitals) an...

SciBase Holding AB Financial Statement Overview

Summary
Revenue is growing and gross margin is solid (~59% TTM), but operating and net losses are extremely large versus revenue (TTM operating margin ~-171%, net margin ~-208%) with deeply negative operating/free cash flow (~-85M TTM). Balance sheet leverage is moderate (debt-to-equity ~0.41), yet persistent losses imply ongoing financing/dilution risk.
Income Statement
22
Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue45.88M40.46M29.70M23.25M17.89M11.73M
Gross Profit26.91M27.10M21.08M16.04M11.23M6.58M
EBITDA-76.00M-81.49M-57.59M-51.83M-39.33M-38.58M
Net Income-95.21M-87.06M-61.13M-55.59M-39.90M-41.69M
Balance Sheet
Total Assets103.69M52.17M61.73M64.33M49.85M85.46M
Cash, Cash Equivalents and Short-Term Investments71.25M22.60M11.24M34.12M18.83M65.61M
Total Debt23.93M0.004.18M6.80M8.12M2.86M
Total Liabilities45.58M45.51M25.08M21.28M24.62M14.66M
Stockholders Equity58.11M6.66M36.65M43.06M25.24M70.80M
Cash Flow
Free Cash Flow-85.38M-84.81M-57.81M-52.37M-44.85M-40.12M
Operating Cash Flow-85.15M-84.58M-57.38M-51.98M-44.47M-39.50M
Investing Cash Flow-228.00K-228.00K-428.00K-383.00K-381.00K-526.00K
Financing Cash Flow122.74M96.29M34.91M67.68M-2.48M64.22M

SciBase Holding AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.33
Price Trends
50DMA
0.39
Positive
100DMA
0.32
Positive
200DMA
0.30
Positive
Market Momentum
MACD
0.03
Negative
RSI
81.18
Negative
STOCH
89.08
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SCIB, the sentiment is Positive. The current price of 0.33 is below the 20-day moving average (MA) of 0.44, below the 50-day MA of 0.39, and above the 200-day MA of 0.30, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 81.18 is Negative, neither overbought nor oversold. The STOCH value of 89.08 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SCIB.

SciBase Holding AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
kr123.91M35.29-12.51%-59.88%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
kr88.86M-3.95-4.00%
47
Neutral
kr519.45M-2.93-253.54%41.17%29.20%
47
Neutral
kr84.52M-2.75-22.86%57.28%
46
Neutral
kr134.17M-4.76-61.62%-29.16%44.24%
43
Neutral
kr38.26M-2.89-60.56%27.31%6.31%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:SCIB
SciBase Holding AB
0.52
0.21
65.50%
SE:CLS.B
Clinical Laserthermia Systems AB Class B
4.35
1.35
45.24%
SE:LXB
Luxbright AB
0.15
-0.62
-80.81%
SE:ARCOMA
Arcoma AB
9.38
-0.24
-2.49%
SE:NEOLA
Neola Medical AB
1.14
-1.42
-55.47%
SE:ICO
Iconovo AB
1.14
-0.04
-3.81%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 14, 2026